MARKET

OMER

OMER

Omeros
NASDAQ
4.780
+0.280
+6.22%
After Hours: 4.740 -0.04 -0.84% 17:17 03/01 EST
OPEN
4.540
PREV CLOSE
4.500
HIGH
4.845
LOW
4.480
VOLUME
436.87K
TURNOVER
0
52 WEEK HIGH
7.80
52 WEEK LOW
0.9200
MARKET CAP
300.50M
P/E (TTM)
14.91
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at OMER last week (0219-0223)?
Weekly Report · 5d ago
Omeros Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use In Nine Patients With Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros to present a report on narsoplimab treatment in nine adult patients with stem cell transplant-associated thrombotic microangiopathy. The report will be featured as a poster presentation at the 2024 Tandem Meetings in San Antonio, Texas. NarsOPlimab is Omeros' investigational antibody targeting MASP-2.
Benzinga · 02/20 14:15
Weekly Report: what happened at OMER last week (0212-0216)?
Weekly Report · 02/19 12:37
Omeros: Still Worth A Look Despite Narsoplimab Woes
Omeros has suffered from underperformance of its Narsoplimab lead therapy OMIDRIA. Omeros is well situated for liquidity over the next two years. The company will need to raise significant funds to continue its operations. The long time lead therapy has been a colossal disappointment for the company.
Seeking Alpha · 02/14 13:30
Weekly Report: what happened at OMER last week (0205-0209)?
Weekly Report · 02/12 12:21
Omeros Expands Royalty Deal with DRI for OMIDRIA Sales
TipRanks · 02/08 09:11
Weekly Report: what happened at OMER last week (0129-0202)?
Weekly Report · 02/05 12:34
Weekly Report: what happened at OMER last week (0122-0126)?
Weekly Report · 01/29 12:16
More
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.